Phase II Trial of Gemcitabine and Docetaxel With Bevacizumab in Soft Tissue Sarcoma
A single-arm phase II trial in p treated with C, D and B (15 mg/kg) every 3 weeks followed by B showed a promising efficacy, in terms of progression free.
